The histone-deacetylase inhibitor MS-275 and the CDK-inhibitor CYC-202 promote anti-tumor effects in hepatoma cell lines

被引：40

作者：

Gahr, Susanne ^{[1
]}

Peter, Gisela ^{[1
]}

Wissniowski, Thadaus Till ^{[1
]}

Hahn, Eckhart G. ^{[1
]}

Herold, Christoph ^{[1
]}

Ocker, Matthias ^{[1
]}

机构：

[1] Univ Hosp Erlangen, Dept Med 1, D-91054 Erlangen, Germany

来源：

ONCOLOGY REPORTS | 2008年 / 20卷 / 05期

关键词：

hepatocellular carcinoma; CYC-202; MS-275; histone deacetylase inhibitor; CDK inhibitor;

D O I：

10.3892/or_00000137

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Effective therapies for advanced stages of hepatocellular carcinoma (HCC) have yet to be developed. We investigated how far a combination of the HDAC inhibitor MS-275 and the CDK inhibitor CYC-202 synergizes to inhibit proliferation and promotes apoptosis of hepatoma cells in vitro. Human hepatoma cell lines Hep3B and HepG2 as well as primary human foreskin fibroblasts as non-malignant controls were cultured under standardized conditions and incubated with increasing concentrations of CYC-202 and MS-275 as single agents and in combination. After 24 to 72 h, apoptosis was analyzed by flow cytometry (propidium iodide, JC-1) and by immunocytochemistry for cytokeratin 18 fragmentation. DNA synthesis was assessed using bromodeoxyuridine incorporation. Protein was separated for Western blotting against p21, bax and bcl-2 and fluorimetric activity assays against caspase 3 and 8. The results showed that the combination of CYC-202 and MS-275 leads to better proapoptotic effects than the employment of single substances. Apoptosis was induced via the mitochondrial pathway as evidenced by a shift in the bax/bcl-2 ratio and breakdown of mitochondrial transmembrane potentials. Caspase assays revealed a strong induction of caspase 3 but not of the extrinsic initiator caspase 8. In conclusion, combination therapy with the biomodulators MS-275 and CYC-202 is a promising treatment option for HCC.

引用

页码：1249 / 1256

页数：8

共 41 条

[1]

Atanasova GN, 2007, ONCOL REP, V18, P999

[2]

Baradari V, 2007, WORLD J GASTROENTERO, V13, P4458

[3] A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days [J].

Benson, C. ;

White, J. ;

De Bono, J. ;

O'Donnell, A. ;

Raynaud, F. ;

Cruickshank, C. ;

McGrath, H. ;

Walton, M. ;

Workman, P. ;

Kaye, S. ;

Cassidy, J. ;

Gianella-Borradori, A. ;

Judson, I. ;

Twelves, C. .

BRITISH JOURNAL OF CANCER, 2007, 96 (01) :29-37

[4] Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies [J].

Bhalla, KN .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (17) :3971-3993

[5] Long-lasting arrest of murine polycystic kidney disease with CDK inhibitor roscovitine [J].

Bukanov, Nikolay O. ;

Smith, Laurie A. ;

Klinger, Katherine W. ;

Ledbetter, Steven R. ;

Ibraghimov-Beskrovnaya, Oxana .

NATURE, 2006, 444 (7121) :949-952

[6] RETRACTED: Histone deacetylase inhibitors sensitize prostate cancer cells to agents that produce DNA double-strand breaks by targeting Ku70 acetylation (Retracted article. See vol. 78, pg. 4097, 2018) [J].

Chen, Chang-Shi ;

Wang, Yu-Chieh ;

Yang, Hsiao-Ching ;

Huang, Po-Hsien ;

Kulp, Samuel K. ;

Yang, Chih-Cheng ;

Lu, Yen-Shen ;

Matsuyama, Shigemi ;

Chen, Ching-Yu ;

Chen, Ching-Shih .

CANCER RESEARCH, 2007, 67 (11) :5318-5327

[7] Cyclin-dependent kinase inhibitors sensitize tumor cells to nutlin-induced apoptosis: a potent drug combination [J].

Cheok, Chit Fang ;

Dey, Anresha ;

Lane, David P. .

MOLECULAR CANCER RESEARCH, 2007, 5 (11) :1133-1145

[8]

Coley HM, 2007, ANTICANCER RES, V27, P273

[9] Treatment of hepatocellular carcinoma [J].

Colombo, M .

JOURNAL OF VIRAL HEPATITIS, 1997, 4 :125-130

[10] R-Roscovitine simultaneously targets both the p53 and NF-κB pathways and causes potentiation of apoptosis:: implications in cancer therapy [J].

Dey, A. ;

Wong, E. T. ;

Cheok, C. F. ;

Tergaonkar, V. ;

Lane, D. P. .

CELL DEATH AND DIFFERENTIATION, 2008, 15 (02) :263-273

← 1 2 3 4 5 →